Clinical trials: A
Acute Leukemia, Myelodysplastic Syndromes
A Study of ONO-7475 in Patients With Acute Leukemias
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability…
- Trial name
- NCT03176277
- Testing
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily
- Where
- 16 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Shoulder Arthroplasty, Total Shoulder Arthroplasty
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
This study is designed to show that the clinical performance of Mirror Anatomic Shoulder Prosthesis meets the performance of currently marketed device in terms of a composite success endpoint (functional score, radiologic…
- Trial name
- NCT07812324
- Testing
- Mirror Anatomic Total Shoulder Prosthesis, Medacta Anatomic Shoulder
- Where
- 12 sites in United States
- Volunteers
- 286 people
- Sponsor
- Medacta USA
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
Bowel Cleansing
Eziclen Drug Utilisation in Real Life Setting
The purpose of the study is to assess Eziclen/Izinova drug utilisation in the real life setting in a representative sample of the European target population.
- Trial name
- DUS-BLI800 (NCT02630680)
- Testing
- Eziclen®/Izinova®
- Where
- 16 sites in Czechia, Germany and 2 more
- Volunteers
- 1,286 people
- Sponsor
- Ipsen
Advanced Solid Tumor
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate Bupropion and metabolite Hydroxy bupropion in Advanced solid tumor…
- Trial name
- NCT04457180
- Testing
- Apatinib Mesylate, Repaglinide, Bupropion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypertension, Hypercholesterinemia
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers
To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.
- Trial name
- NCT05372380
- Testing
- BR1017-1, BR1017-2
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Alzheimer Disease, MCI
Validation Study of a New Digital Diagnostic and Treatment Test Based on Interactive Video Games for Alzheimer's Disease
This study aims to validate a novel, non-invasive diagnostic and digital therapeutic approach for Alzheimer's Disease (AD), centered on an interactive video game called BGaze Therapy.
- Trial name
- EyeAD (NCT06963879)
- Testing
- Bgaze Therapy, Bgaze Attention Task
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Braingaze
Advanced Solid Tumor
A Study of HS-20089 in Patients With Advanced Solid Tumors
HS-20089 is a novel DAR-6 antibody-drug conjugate （ADC） targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo.
- Trial name
- NCT05263479
- Testing
- HS-20089 (Phase Ia：Dose escalation ), HS-20089 (Phase Ib: Dose expansion)
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
Mucus Clearance, Respiratory Symptoms
A Study to Evaluate the Effects of a Supplement on Mucus Clearance and Respiratory Symptoms
This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of the BetterLungs Mullein + Chlorophyll supplement on mucus clearance and respiratory symptoms over 60 days.
- Conditions
- Mucus Clearance, Respiratory Symptoms, Breathlessness, Chest Mucus Accumulation
- Trial name
- NCT07740746
- Testing
- BetterLungs
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Better Brand Inc.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
Vaccine Response Impaired
Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
This study evaluated whether it is possible in healthy elderly participants to generate baseline biomarker-based prediction rules (PdR) for vaccine response (post baseline absolute serum antibody titer) using each of the protocol…
- Trial name
- NCT01119703
- Testing
- Tetanus & Diphtheria booster vaccine (Td), TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Gastrointestinal Dysfunction
An Efficacy Trial in the Research Area of Gastrointestinal Health & Bloating
A randomized, double-blinded, placebo-controlled, parallel study, to evaluate the effect of 8-week supplementation of a traditionally fermented organic coconut milk kefir compared to placebo on gastrointestinal symptoms in…
- Trial name
- NCT05418127
- Testing
- Active
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Coconut Goodness Food Products Inc.
Interdigital Tinea Pedis
Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show…
- Trial name
- BNF-0909 (NCT01119742)
- Testing
- Butenafine Hydrochloride 1%, Butenafine Hydrochloride 1% B, Vehicle A
- Volunteers
- 428 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Amputation, Prosthesis User
Effects of Microprocessor-controlled Prosthetic Knees on Fall-related Health Outcomes in Limited Community Ambulators
The goal of this study is to find out if using microprocessor-controlled prosthetic knees (MPKs), prosthetic knees with a built-in computer, improves health outcomes related to falls in adults who use above-knee prostheses.
- Conditions
- Amputation, Prosthesis User, Amputation; Traumatic, Leg: Thigh, Between Hip and Knee, Limb; Absence, Congenital, Lower
- Trial name
- NCT06937242
- Testing
- Ottobock C-Leg 4 Microprocessor Knee, Ottobock Kenevo
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Hanger Institute for Clinical Research and Education, LLC
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3…
- Trial name
- NCT03706469
- Testing
- TAK-831 T2, TAK-831 T3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Healthy
A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.
The purpose of this study is to see how rabeprazole affects the level of the study medicine sisunatovir in the blood of healthy adult participants. Rabeprazole is a medicine that reduces the amount of acid the stomach makes.
- Trial name
- NCT06105983
- Testing
- Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-infectious Anterior Uveitis
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
- Trial name
- NCT03131154
- Testing
- ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
- Where
- 27 sites in United States
- Volunteers
- 123 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Healthy
A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers
This study is designed as a single centre, double blind, placebo controlled, randomized, SAD/FE/MAD, safety, tolerance and PK study of BMB-101 in healthy adult subjects. The study will be conducted as a 3-part study.
- Trial name
- NCT05397041
- Testing
- BMB-101
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Bright Minds Biosciences Pty Ltd
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.